Drug intelligence / Profile preview

V184

Development stage: Phase 2
Lead developer: Merck
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

V184 is an investigational recombinant live attenuated vaccine developed by Themis Bioscience GmbH. It utilizes a Schwarz-strain measles virus vector to express chikungunya virus structural proteins. The vaccine is designed to induce an immune response against the chikungunya virus, aiming to prevent chikungunya infection. It is administered via intramuscular injection.

Targets

CHIKV structural polyprotein (Chikungunya virus structural polyprotein)

Beyond the preview

Go deeper on V184.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V184.

Explore the full profile